Neuroleptic malignant syndrome with risperidone

Patrick P. Gleason, Rosemarie L. Conigliaro

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia. Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade. The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages. With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered. A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone. The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine. It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.

Original languageEnglish (US)
Pages (from-to)617-621
Number of pages5
JournalPharmacotherapy
Volume17
Issue number3
StatePublished - May 1 1997

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Neuroleptic malignant syndrome with risperidone'. Together they form a unique fingerprint.

  • Cite this

    Gleason, P. P., & Conigliaro, R. L. (1997). Neuroleptic malignant syndrome with risperidone. Pharmacotherapy, 17(3), 617-621.